SAT0338 Survival in a turkish inflammatory myositis cohort: a single-centre study

Background Inflammatory myositis is an uncommon group of diseases that can be associated with significant morbidity and mortality related to systemic involvement or treatment-related complications. Objectives This study aimed to describe the clinical features and survival of patients with inflammatory myositis in our centre. Methods We performed a single-centre, retrospective study on patients with inflammatory myositis (polymyositis [PM], dermatomyositis [DM], or Anti-Jo1 syndrome) seen from 2000 to 2014, noting their demographic data, clinical features and outcome until December 2016. The primary outcome assessed was all-cause mortality. Cumulative mortality rates were estimated using the Kaplan-Meier test; the Log Rank (Mantle-Cox) test was used to compare subgroup differences in survival. Results Seventy-four patients (19 PM, 28 DM, 27 Anti-Jo1 syndrome) were available for the study. Median age at diagnosis was 47 years (min 17, max 75) and median follow-up time was 93 months (min 4, max 311). Sixty-one patients (82, 4%) were female and 13 (17, 6%) were male. Malignancy was found in 4 patients (2 invasive ductal adenocancer of breast, 1 over cancer and 1 non-small cell lung cancer) and they were all female DM patients. Nineteen patients (25,7%) died at the end of the follow-up. The 19 patients with PM consisted of 15 female and 6 male, with a median age at diagnosis of 45 years (min 22, max 74) and median follow-up time of 88 months (min 5, max 204). The 28 patients with DM consisted of 24 female and 4 male, with a median age at diagnosis of 52 years (min 17, max 75) and median follow-up time of 80 months (min 4, max 288). The 27 patients with Anti-Jo1 syndrome consisted of 22 female and 5 male, with a median age at diagnosis of 50 years (min 22, max 63) and median follow-up time of 117 months (min 5, max 311). Overall survival rates of the whole group were 91%, 83%, and 76% for 1, 5, and 10 years, respectively. The survival rates at 1, 5 and 10 years from the diagnosis were respectively 88%, 82%, %82 for PM, %88, 80%, %80 for DM and 96%, 88%, 74,5% for Anti-Jo1 syndrome. But there was no significant difference between the survival rates of the diagnose groups (p=0,734). Also there wasn9t a significant difference between the survival rates of sex and age groups (p=0,503), (p=0,112). But the survival rates were significantly lower in patients with the time from diagnose less than 8 years (p=0,000). Conclusions Our study involved 74 patients followed up for a median of 7, 7 years and is one of the largest cohorts of patients with inflammatory myositis in Turkey. Survival was quite similar with the literature. Usually mortality has been expected in the first years after the diagnosis. Disclosure of Interest None declared